生物
炎症性肠病
维多利祖马布
丁酸盐
克罗恩病
肠道菌群
疾病
肠易激综合征
溃疡性结肠炎
普氏粪杆菌
代谢组
免疫学
代谢组学
胃肠病学
内科学
生物信息学
医学
食品科学
发酵
作者
Chen Wang,Yu Gu,Qiao Chu,Xin Wang,Yiyun Ding,Xiali Qin,Tianyu Liu,Sinan Wang,Xiang Liu,Bangmao Wang,Hailong Cao
标识
DOI:10.1016/j.micres.2024.127660
摘要
Nonresponse to biologic agents in patients with inflammatory bowel disease (IBD) poses a significant public health burden, and the prediction of response to biologics offers valuable insights for IBD management. Given the pivotal role of gut microbiota and their endogenous metabolites in IBD, we conducted a systematic review to investigate the potential of fecal microbiota and mucosal microbiota and endogenous metabolomic markers as predictors for biotherapy response in IBD patients. A total of 38 studies were included in the review. Following anti-TNF-α treatment, the bacterial community characteristics of IBD patients exhibited a tendency to resemble those observed in healthy controls, indicating an improved clinical response. The levels of endogenous metabolites butyrate and deoxycholic acid were significantly associated with clinical remission following anti-TNF-α therapy. IBD patients who responded well to vedolizumab treatment had higher levels of specific bacteria that produce butyrate, along with increased levels of metabolites such as butyrate, branched-chain amino acids and acetamide following vedolizumab treatment. Crohn's disease patients who responded positively to ustekinumab treatment showed higher levels of Faecalibacterium and lower levels of Escherichia/Shigella. In conclusion, fecal microbiota and mucosal microbiota as well as their endogenous metabolites could provide a predictive tool for assessing the response of IBD patients to various biological agents and serve as a valuable reference for precise drug selection in clinical IBD patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI